

Richard M Weinshilboum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4747028/publications.pdf>

Version: 2024-02-01

273
papers

20,397
citations

18482

62
h-index

12272

133
g-index

288
all docs

288
docs citations

288
times ranked

17957
citing authors

#	ARTICLE	IF	CITATIONS
1	Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 243-250.	5.7	1,681
2	Inheritance and Drug Response. <i>New England Journal of Medicine</i> , 2003, 348, 529-537.	27.0	961
3	CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 30-39.	6.3	867
4	Metabolomics: A Global Biochemical Approach to Drug Response and Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 653-683.	9.4	599
5	Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 149-154.	4.7	583
6	Genomics and Drug Response. <i>New England Journal of Medicine</i> , 2011, 364, 1144-1153.	27.0	552
7	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 113-121.	2.5	520
8	METHYLATION PHARMACOGENETICS: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase. <i>Annual Review of Pharmacology and Toxicology</i> , 1999, 39, 19-52.	9.4	513
9	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1429.	7.4	468
10	Sulfotransferase molecular biology: cDNAs and genes. <i>FASEB Journal</i> , 1997, 11, 3-14.	0.5	398
11	Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 60-73.	4.7	384
12	Serum Dopamine-Beta-Hydroxylase Activity. <i>Circulation Research</i> , 1971, 28, 307-315.	4.5	339
13	Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 18-25.	4.7	334
14	Thiopurine Methyltransferase Pharmacogenetics: Human Gene Cloning and Characterization of a Common Polymorphism. <i>DNA and Cell Biology</i> , 1996, 15, 17-30.	1.9	309
15	Pharmacogenomics: bench to bedside. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 739-748.	46.4	293
16	Phenol Sulfotransferase Pharmacogenetics in Humans: Association of Common SULT1A1 Alleles with TS PST Phenotype. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 298-304.	2.1	285
17	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	7.4	257
18	Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment Protocol. <i>Mayo Clinic Proceedings</i> , 2014, 89, 25-33.	3.0	250

#	ARTICLE	IF	CITATIONS
19	Chapter 6: Estrogen Metabolism by Conjugation. Journal of the National Cancer Institute Monographs, 2000, 2000, 113-124.	2.1	239
20	Pharmacogenomics: Challenges and Opportunities. Annals of Internal Medicine, 2006, 145, 749.	3.9	228
21	Human liver catechol-O-methyltransferase pharmacogenetics. Clinical Pharmacology and Therapeutics, 1990, 48, 381-389.	4.7	226
22	Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annual Review of Genomics and Human Genetics, 2006, 7, 223-245.	6.2	203
23	Human liver thiopurine methyltransferase pharmacogenetics. Pharmacogenetics and Genomics, 1992, 2, 148-159.	5.7	201
24	Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. Journal of Clinical Oncology, 2010, 28, 4674-4682.	1.6	196
25	Human Aromatase: Gene Resequencing and Functional Genomics. Cancer Research, 2005, 65, 11071-11082.	0.9	185
26	Human phenol sulfotransferases SULT1A2 and SULT1A1. Biochemical Pharmacology, 1999, 58, 605-616.	4.4	180
27	Preemptive Pharmacogenomic Testing for Precision Medicine. Journal of Molecular Diagnostics, 2016, 18, 438-445.	2.8	171
28	The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases. International Journal of Molecular Sciences, 2018, 19, 3851.	4.1	161
29	Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clinic Proceedings, 2017, 92, 1711-1722.	3.0	156
30	Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clinical Pharmacology and Therapeutics, 1997, 62, 464-475.	4.7	148
31	Genome-wide association studies in pharmacogenomics. Pharmacogenetics and Genomics, 2013, 23, 383-394.	1.5	144
32	Clopidogrel Pharmacogenetics. Circulation: Cardiovascular Interventions, 2019, 12, e007811.	3.9	139
33	Human Histamine N-Methyltransferase Pharmacogenetics: Common Genetic Polymorphisms that Alter Activity. Molecular Pharmacology, 1998, 53, 708-717.	2.3	135
34	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. Journal of Clinical Investigation, 2018, 128, 2376-2388.	8.2	134
35	Human kidney thiopurine methyltransferase purification and biochemical properties. Biochemical Pharmacology, 1983, 32, 819-826.	4.4	128
36	Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenetics and Genomics, 2005, 15, 801-815.	1.5	127

#	ARTICLE	IF	CITATIONS
37	CYP2C19 variation and citalopram response. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 1-9.	1.5	126
38	Genetics of red cell COMT activity: Analysis of thermal stability and family data. <i>American Journal of Medical Genetics Part A</i> , 1981, 10, 279-290.	2.4	120
39	Human Arsenic Methyltransferase (AS3MT) Pharmacogenetics. <i>Journal of Biological Chemistry</i> , 2006, 281, 7364-7373.	3.4	119
40	Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 210-219.	4.7	111
41	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	4.7	110
42	Human liver xanthine oxidase: Nature and extent of individual variation. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 663-672.	4.7	109
43	Thermolabile and thermostable human platelet phenol sulfotransferase. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1983, 324, 140-147.	3.0	106
44	Intensification of Mercaptopurine/Methotrexate Maintenance Chemotherapy May Increase the Risk of Relapse for Some Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 1332-1339.	1.6	106
45	Nomenclature for alleles of the thiopurine methyltransferase gene. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 242-248.	1.5	104
46	Human thiopurine S-methyltransferase pharmacogenetics: Variant allozyme misfolding and aggresome formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9394-9399.	7.1	103
47	Human SULT1A1 gene: copy number differences and functional implications. <i>Human Molecular Genetics</i> , 2007, 16, 463-470.	2.9	102
48	Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity. <i>Biochemical Genetics</i> , 1982, 20, 637-658.	1.7	100
49	Catecholestrogen Sulfation: Possible Role in Carcinogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 402-408.	2.1	100
50	Methyltransferase pharmacogenetics. , 1989, 43, 77-90.		91
51	Thiopurine S-methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 555-564.	5.7	90
52	Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 261-266.	5.7	89
53	Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. <i>British Journal of Pharmacology</i> , 2003, 139, 1373-1382.	5.4	87
54	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 70-70.	46.4	80

#	ARTICLE	IF	CITATIONS
55	GLUTATHIONE S-TRANSFERASE OMEGA 1 AND OMEGA 2 PHARMACOGENOMICS. Drug Metabolism and Disposition, 2006, 34, 1237-1246.	3.3	77
56	Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers. PLoS ONE, 2009, 4, e7765.	2.5	75
57	Glutathione S-Transferase P1: Gene Sequence Variation and Functional Genomic Studies. Cancer Research, 2008, 68, 4791-4801.	0.9	74
58	Multidisciplinary model to implement pharmacogenomics at the point of care. Genetics in Medicine, 2017, 19, 421-429.	2.4	74
59	Analysis of the distribution of erythrocyte sodium lithium countertransport in a sample representative of the general population. Genetic Epidemiology, 1986, 3, 365-378.	1.3	72
60	Glutathione S-Transferase T1 and M1: Gene Sequence Variation and Functional Genomics. Clinical Cancer Research, 2007, 13, 7207-7216.	7.0	69
61	Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine Learning Approach With Multi-Trial Replication. Clinical Pharmacology and Therapeutics, 2019, 106, 855-865.	4.7	69
62	Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. British Journal of Clinical Pharmacology, 2014, 78, 373-383.	2.4	67
63	Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genetics in Medicine, 2020, 22, 475-486.	2.4	67
64	Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. Molecular Psychiatry, 2019, 24, 808-818.	7.9	66
65	Human platelet phenol sulfotransferase: Familial variation in thermal stability of the TS form. Biochemical Genetics, 1984, 22, 997-1014.	1.7	64
66	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.7	64
67	Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Molecular Psychiatry, 2019, 24, 795-807.	7.9	64
68	Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. Cancer Research, 2010, 70, 3278-3286.	0.9	63
69	Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature, 1974, 252, 490-491.	27.8	62
70	Human Indolethylamine N-Methyltransferase: cDNA Cloning and Expression, Gene Cloning, and Chromosomal Localization. Genomics, 1999, 61, 285-297.	2.9	62
71	Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochemical and Biophysical Research Communications, 2004, 321, 870-878.	2.1	61
72	Merging pharmacometabolomics with pharmacogenomics using ~1000 Genomes™ single-nucleotide polymorphism imputation. Pharmacogenetics and Genomics, 2012, 22, 247-253.	1.5	61

#	ARTICLE	IF	CITATIONS
73	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 812-825.	9.4	61
74	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	61
75	Human erythrocyte thiol methyltransferase: Radiochemical microassay and biochemical properties. <i>Clinica Chimica Acta</i> , 1979, 97, 59-71.	1.1	60
76	Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. <i>Breast Cancer Research</i> , 2012, 14, R41.	5.0	60
77	Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. <i>Human Psychopharmacology</i> , 2016, 31, 185-192.	1.5	60
78	Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: Common gene sequence variation and functional characterization. <i>Molecular Genetics and Metabolism</i> , 2008, 94, 326-335.	1.1	59
79	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. <i>Translational Psychiatry</i> , 2018, 8, 10.	4.8	59
80	Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 265-277.	1.5	58
81	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , 2020, 30, 590-601.	12.0	58
82	Human erythrocyte catechol-o-methyltransferase: Correlation with lung and kidney activity. <i>Life Sciences</i> , 1978, 22, 625-630.	4.3	56
83	The therapeutic revolution. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 481-484.	4.7	56
84	Purine substrates for human thiopurine methyltransferase. <i>Biochemical Pharmacology</i> , 1994, 48, 2135-2138.	4.4	55
85	Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. <i>Journal of Neurochemistry</i> , 2003, 87, 809-819.	3.9	55
86	FKBP5 genetic variation. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 156-166.	1.5	54
87	Pharmacogenomics: candidate gene identification, functional validation and mechanisms. <i>Human Molecular Genetics</i> , 2008, 17, R174-R179.	2.9	53
88	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	5.0	53
89	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , 2019, 9, 173.	4.8	53
90	Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 747-756.	5.7	52

#	ARTICLE	IF	CITATIONS
91	Inheritance of human platelet thermolabile phenol sulfotransferase (TL PST) activity. Genetic Epidemiology, 1988, 5, 1-15.	1.3	51
92	Pharmacogenomics: Catechol O-Methyltransferase to Thiopurine S-Methyltransferase. Cellular and Molecular Neurobiology, 2006, 26, 537-559.	3.3	51
93	Segregation analysis of human red blood cell thiopurine methyltransferase activity. Genetic Epidemiology, 1995, 12, 1-11.	1.3	49
94	Pharmacogenomics and Patient Care: One Size Does Not Fit All. Science Translational Medicine, 2012, 4, 153ps18.	12.4	49
95	TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. Molecular Endocrinology, 2013, 27, 657-670.	3.7	49
96	Human NicotinamideN-Methyltransferase Gene: Molecular Cloning, Structural Characterization and Chromosomal Localization. Genomics, 1995, 29, 555-561.	2.9	48
97	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	48
98	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research, 2016, 76, 7012-7023.	0.9	47
99	Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. Journal of Neurochemistry, 2005, 95, 1766-1776.	3.9	46
100	Treatment Outcomes of Depression. Journal of Clinical Psychopharmacology, 2014, 34, 313-317.	1.4	46
101	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 2021, 11, 153.	4.8	46
102	Sulfation pharmacogenetics in humans. Chemico-Biological Interactions, 1994, 92, 233-246.	4.0	45
103	Pharmacogenetics of N-methylation: Heritability of human erythrocyte histamine N-methyltransferase activity. Clinical Pharmacology and Therapeutics, 1988, 43, 256-262.	4.7	44
104	Pharmacometabolomics informs pharmacogenomics. Metabolomics, 2016, 12, 1.	3.0	43
105	Human Estrogen Sulfotransferase Gene (STE): Cloning, Structure, and Chromosomal Localization. Genomics, 1995, 29, 16-23.	2.9	42
106	Severe 6-Thioguanine-induced Marrow Aplasia in a Child With Acute Lymphoblastic Leukemia and Inherited Thiopurine Methyltransferase Deficiency. The American Journal of Pediatric Hematology/oncology, 2000, 22, 441-445.	1.3	42
107	Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenetics and Genomics, 2010, 20, 401-405.	1.5	42
108	Catechol-O-methyltransferase biochemical genetics: Human lymphocyte enzyme. Biochemical Genetics, 1981, 19, 1037-1053.	1.7	40

#	ARTICLE	IF	CITATIONS
109	Pharmacogenomics and reducing the frequency of adverse drug events. <i>Pharmacogenomics</i> , 2003, 4, 1-4.	1.3	40
110	Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 253-258.	4.7	40
111	Therapeutic potential of triterpenoid saponin anemoside B4 from <i>Pulsatilla chinensis</i> . <i>Pharmacological Research</i> , 2020, 160, 105079.	7.1	39
112	Breast Cancer Risk Reduction and Membrane-Bound Catechol <i>O</i> -Methyltransferase Genetic Polymorphisms. <i>Cancer Research</i> , 2008, 68, 5997-6005.	0.9	38
113	Betaine-homocysteine methyltransferase: Human liver genotypeâ€“phenotype correlation. <i>Molecular Genetics and Metabolism</i> , 2011, 102, 126-133.	1.1	38
114	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , 2015, 99, 32-38.	1.8	38
115	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65.	2.6	38
116	Thiol methylation pharmacogenetics: Heritability of human erythrocyte thiol methyltransferase activity. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 521-528.	4.7	37
117	Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5â€²-flanking region single nucleotide polymorphism (SNP). <i>Biochemical Pharmacology</i> , 2002, 64, 699-710.	4.4	37
118	Human HistamineN-Methyltransferase Gene: Structural Characterization and Chromosomal Localization. <i>Biochemical and Biophysical Research Communications</i> , 1996, 219, 548-554.	2.1	36
119	The lncRNA MIR2052HG regulates ERÎ± levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. <i>Breast Cancer Research</i> , 2019, 21, 47.	5.0	36
120	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	4.1	36
121	The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2000, 23, 143-148.	0.7	35
122	Maintenance therapy of childhood acute lymphoblastic leukemia revisitedâ€“Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2104-2111.	1.5	35
123	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. <i>Biochemical Pharmacology</i> , 2018, 152, 279-292.	4.4	35
124	Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. <i>IEEE Computational Intelligence Magazine</i> , 2018, 13, 20-31.	3.2	34
125	Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). <i>International Journal of Epidemiology</i> , 2020, 49, 23-24k.	1.9	34
126	Knowledge-guided analysis of "omics" data using the KnowEnG cloud platform. <i>PLoS Biology</i> , 2020, 18, e3000583.	5.6	34

#	ARTICLE	IF	CITATIONS
127	A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?. <i>Genetics in Medicine</i> , 2021, 23, 461-470.	2.4	34
128	Mouse Liver Nicotinamide N-Methyltransferase:. <i>Biochemical Pharmacology</i> , 1997, 54, 1139-1149.	4.4	33
129	The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. <i>Nucleic Acids Research</i> , 2014, 42, e172-e172.	14.5	33
130	<i>CYP2C9</i> and <i>CYP2C19</i> : Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants. <i>Clinical and Translational Science</i> , 2020, 13, 727-742.	3.1	33
131	Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 555-64.	5.7	33
132	Structural Basis of Substrate Recognition in Thiopurine S-Methyltransferase. <i>Biochemistry</i> , 2008, 47, 6216-6225.	2.5	32
133	Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. <i>BMJ Open</i> , 2016, 6, e010332.	1.9	32
134	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	3.3	32
135	Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine. <i>Frontiers in Pharmacology</i> , 2019, 10, 1302.	3.5	32
136	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	5.1	31
137	Effect of Resveratrol on 17β -Estradiol Sulfation by Human Hepatic and Jejunal S9 and Recombinant Sulfotransferase 1E1. <i>Drug Metabolism and Disposition</i> , 2008, 36, 129-136.	3.3	30
138	Sulfate and methyl dopa metabolism: Metabolite patterns and platelet phenol sulfotransferase activity. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 308-315.	4.7	29
139	Human erythrocyte histamine N-methyltransferase: radiochemical microassay and biochemical properties. <i>Clinica Chimica Acta</i> , 1985, 149, 237-251.	1.1	29
140	Primer on Medical Genomics: Part XII: Pharmacogenomics—General Principles With Cancer as a Model. <i>Mayo Clinic Proceedings</i> , 2004, 79, 376-384.	3.0	29
141	Human Hydroxysteroid Sulfotransferase SULT2B1 Pharmacogenomics: Gene Sequence Variation and Functional Genomics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 529-540.	2.5	29
142	Cytosolic 5-nucleotidase III (NT5C3): gene sequence variation and functional genomics. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 567-576.	1.5	29
143	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , 2018, 238, 1-7.	4.1	28
144	Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. <i>Genetics in Medicine</i> , 2022, 24, 1062-1072.	2.4	28

#	ARTICLE	IF	CITATIONS
145	Sulfation pharmacogenetics: Correlation of human platelet and small intestinal phenol sulfotransferase. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 501-509.	4.7	27
146	Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 1083-1094.	1.5	27
147	Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. <i>Molecular Endocrinology</i> , 2016, 30, 382-398.	3.7	27
148	TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 201-210.	4.7	27
149	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	2.8	27
150	Monogenic inheritance of catechol-O-methyltransferase activity in the rat—biochemical and genetic studies. <i>Biochemical Pharmacology</i> , 1979, 28, 1239-1247.	4.4	26
151	Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. <i>PLoS ONE</i> , 2015, 10, e0145176.	2.5	26
152	Human nicotinamide N-methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 307-316.	5.7	24
153	Theoretical 3D Model of Histamine N-Methyltransferase: Insights into the Effects of a Genetic Polymorphism on Enzymatic Activity and Thermal Stability. <i>Biochemical and Biophysical Research Communications</i> , 2001, 287, 204-208.	2.1	24
154	Natriuretic peptide pharmacogenetics: Membrane metallo-endopeptidase (MME): Common gene sequence variation, functional characterization and degradation. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 864-874.	1.9	24
155	Major gene model for the inheritance of catechol-o-methyltransferase activity in five large families. <i>American Journal of Medical Genetics Part A</i> , 1984, 19, 315-323.	2.4	23
156	Genetic segregation analysis of red blood cell (RBC) histamineN-methyltransferase (HNMT) activity. <i>Genetic Epidemiology</i> , 1993, 10, 123-131.	1.3	23
157	Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. <i>Breast Cancer Research</i> , 2017, 19, 95.	5.0	22
158	SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER±-positive breast cancer through regulation of BRCA1. <i>PLoS Genetics</i> , 2017, 13, e1007031.	3.5	22
159	Mouse liver nicotinamide N-methyltransferase pharmacogenetics: biochemical properties and variation in activity among inbred strains. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 43-53.	5.7	21
160	Canine red blood cell thiopurine S-methyltransferase. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 713-724.	5.7	21
161	Thiopurine Methyltransferase Activity in Red Blood Cells of Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 214-218.	1.6	21
162	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 158.	3.5	21

#	ARTICLE	IF	CITATIONS
163	Thiopurine methyltransferase: mouse kidney and liver assay conditions, biochemical properties and strain variation. <i>Biochemical Pharmacology</i> , 1985, 34, 3823-3830.	4.4	20
164	Histamine N-methyltransferase functional polymorphism: Lack of association with schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 404-406.	2.4	20
165	Human 3 β -hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 107, 88-99.	2.5	20
166	Methionine Adenosyltransferase 2A/2B and Methylation: Gene Sequence Variation and Functional Genomics. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2135-2147.	3.3	20
167	Pharmacogenomics of Endocrine Therapy in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 630, 220-231.	1.6	20
168	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. <i>Translational Psychiatry</i> , 2021, 11, 513.	4.8	20
169	Copy number variation and cytidine analogue cytotoxicity: A genome-wide association approach. <i>BMC Genomics</i> , 2010, 11, 357.	2.8	19
170	Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 59-66.	2.3	19
171	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. <i>Neuropsychopharmacology</i> , 2021, 46, 2132-2139.	5.4	19
172	Human kidney thiopurine methyltransferase. <i>Biochemical Pharmacology</i> , 1992, 44, 775-785.	4.4	18
173	Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1123-1128.	3.3	18
174	Thiopurine S-methyltransferase pharmacogenetics: Functional characterization of a novel rapidly degraded variant allozyme. <i>Biochemical Pharmacology</i> , 2010, 79, 1053-1061.	4.4	18
175	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. <i>Npj Breast Cancer</i> , 2017, 3, 30.	5.2	18
176	TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor- κ B Activation: Single-Nucleotide Polymorphism and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response. <i>Molecular Pharmacology</i> , 2017, 92, 175-184.	2.3	18
177	Major gene polymorphism for human erythrocyte (RBC) thiol methyltransferase (TMT). <i>Genetic Epidemiology</i> , 1989, 6, 651-662.	1.3	17
178	Cat Red Blood Cell Thiopurine S-Methyltransferase: Companion Animal Pharmacogenetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 617-626.	2.5	17
179	Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated With Stroke in Whites. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 141-149.	5.1	17
180	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 189-199.	2.5	17

#	ARTICLE	IF	CITATIONS
181	The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer. <i>Cancer & Metabolism</i> , 2019, 7, 1.	5.0	17
182	Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in <i>CYP2C9</i> and <i>CYP2C19</i> . <i>Drug Metabolism and Disposition</i> , 2019, 47, 425-435.	3.3	17
183	ERICH3: vesicular association and antidepressant treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 2415-2428.	7.9	17
184	TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 3122-3133.	7.9	17
185	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor I±. <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	7.0	17
186	<i>SLCO1B1</i> : Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function. <i>Drug Metabolism and Disposition</i> , 2021, 49, 395-404.	3.3	17
187	Ecto-5â€²-Nucleotidase and Thiopurine Cellular Circulation: Association with Cytotoxicity. <i>Drug Metabolism and Disposition</i> , 2010, 38, 2329-2338.	3.3	16
188	Human Liver Methionine Cycle: <i>MAT1A</i> and <i>GNMT</i> Gene Resequencing, Functional Genomics, and Hepatic Genotype-Phenotype Correlation. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1984-1992.	3.3	16
189	Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure. , 2018, , .		16
190	<i>SLCO1B1</i> genetic variation and hormone therapy in menopausal women. <i>Menopause</i> , 2018, 25, 877-882.	2.0	16
191	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. <i>Journal of Affective Disorders</i> , 2019, 246, 62-68.	4.1	16
192	TCF7L2 lncRNA: a link between bipolar disorder and body mass index through glucocorticoid signaling. <i>Molecular Psychiatry</i> , 2021, 26, 7454-7464.	7.9	16
193	Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. <i>Biochemical and Biophysical Research Communications</i> , 2004, 325, 426-433.	2.1	15
194	CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. <i>Leukemia and Lymphoma</i> , 2010, 51, 1315-1325.	1.3	15
195	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, 926.	2.8	15
196	Comparison of ^{99m} Tc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>American Journal of Roentgenology</i> , 2019, 213, 932-943.	2.2	15
197	Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. <i>Oncotarget</i> , 2017, 8, 27199-27215.	1.8	15
198	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15

#	ARTICLE	IF	CITATIONS
199	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <sc>Pharmacogenomics-Driven</sc> Machine Learning Approach. <i>Arthritis Care and Research</i> , 2022, 74, 879-888.	3.4	15
200	Metformin Pharmacogenomics: Biomarkers to Mechanisms. <i>Diabetes</i> , 2014, 63, 2609-2610.	0.6	14
201	Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1233-1242.	4.7	14
202	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. <i>Neuropsychopharmacology</i> , 2021, 46, 1272-1282.	5.4	14
203	Linkage relationships between a major gene for catechol-o-methyltransferase activity and 25 polymorphic marker systems. <i>American Journal of Medical Genetics Part A</i> , 1984, 19, 525-532.	2.4	13
204	Histamine N-methyltransferase: Inhibition by monoamine oxidase inhibitors. <i>Agents and Actions</i> , 1993, 40, 1-10.	0.7	13
205	Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET). <i>Genome Medicine</i> , 2013, 5, 7.	8.2	13
206	KnowEnG: a knowledge engine for genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1115-1119.	4.4	13
207	Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand-Dependent Gene Expression. <i>Drug Metabolism and Disposition</i> , 2019, 47, 983-994.	3.3	13
208	Targeted Genotyping in Clinical Pharmacogenomics. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 253-261.	2.8	13
209	Natriuretic Peptide Receptor-3 Gene (NPR3). <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 201-210.	5.1	12
210	Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. <i>Physiological Genomics</i> , 2008, 33, 323-332.	2.3	11
211	Human S-adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization. <i>Journal of Neurochemistry</i> , 2009, 110, 1806-1817.	3.9	11
212	Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 577-587.	1.5	11
213	Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1372-1381.	3.3	11
214	Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 662-670.	4.7	11
215	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. <i>Oncotarget</i> , 2019, 10, 3924-3930.	1.8	11
216	Chronic cortisol differentially impacts stem cell-derived astrocytes from major depressive disorder patients. <i>Translational Psychiatry</i> , 2021, 11, 608.	4.8	11

#	ARTICLE	IF	CITATIONS
217	Methylenetetrahydrofolate Reductase Haplotype Tag Single-Nucleotide Polymorphisms and Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2322-2324.	2.5	10
218	Mycophenolic acid response biomarkers: A cell line model system-based genome-wide screen. <i>International Immunopharmacology</i> , 2011, 11, 1057-1064.	3.8	10
219	Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1531-1539.	2.4	10
220	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	1.0	10
221	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 219-227.	4.7	10
222	Selective Serotonin Reuptake Inhibitor Pharmacogenomics: Mechanisms and Prediction. <i>Frontiers in Pharmacology</i> , 2020, 11, 614048.	3.5	10
223	Pharmacogenomics: Bench to bedside. <i>Discovery Medicine</i> , 2005, 5, 30-6.	0.5	10
224	Prolonged hypouricemia associated with acute chlorprothixene ingestion. <i>Arthritis and Rheumatism</i> , 1975, 18, 739-742.	6.7	9
225	A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. <i>Scientific Reports</i> , 2016, 6, 37003.	3.3	9
226	TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κ B p65: Single Nucleotide Polymorphism and Estrogen Dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 700-710.	2.5	9
227	Pharmacogenomics in Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 936-938.	4.7	9
228	Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments?. <i>Pharmacogenomics</i> , 2019, 20, 983-988.	1.3	9
229	Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods. , 2017, , .		7
230	Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 767-769.	4.7	7
231	Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 243-252.	4.7	7
232	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	7.0	7
233	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 412.	2.5	7
234	Pharmacogenetics of methyl conjugation and thiopurine drug toxicity. <i>BioEssays</i> , 1987, 7, 78-82.	2.5	6

#	ARTICLE	IF	CITATIONS
235	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor $\hat{\pm}$ -positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 567-578.	2.5	6
236	Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort. <i>PLoS ONE</i> , 2020, 15, e0233316.	2.5	6
237	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	2.6	6
238	Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. <i>Oncotarget</i> , 2017, 8, 78133-78143.	1.8	6
239	Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1296-1306.	4.7	6
240	Mouse Nicotinamide N-Methyltransferase Gene: Molecular Cloning, Structural Characterization, and Chromosomal Localization. <i>DNA and Cell Biology</i> , 1998, 17, 659-667.	1.9	5
241	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014, 207, 19-30.	0.4	5
242	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	4.7	5
243	Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX). <i>Npj Breast Cancer</i> , 2021, 7, 79.	5.2	5
244	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1854-1862.	7.0	5
245	Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism. <i>Molecular Metabolism</i> , 2022, 63, 101534.	6.5	5
246	Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	4
247	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. <i>Journal of Psychiatric Research</i> , 2017, 95, 208-212.	3.1	4
248	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 147-152.	1.5	4
249	Catechol O-Methyltransferase Pharmacogenomics: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 281-283.	4.7	4
250	Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 206-216.	4.1	4
251	Electrophysiological Neuroimaging using sLORETA Comparing 22 Age Matched Male and Female Schizophrenia Patients. <i>Hospital Chronicles</i> , 2015, 10, 91-98.	1.0	4
252	Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. <i>British Journal of Pharmacology</i> , 2022, , .	5.4	4

#	ARTICLE	IF	CITATIONS
253	Erythrocyte Catechol-O-Methyltransferase, Platelet Monoamine Oxidase, and Platelet Phenol Sulfotransferase Activities in Patients with Prolactin Secreting Pituitary Adenomas*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1207-1210.	3.6	3
254	Inheritance of human plasma dopamine-β-hydroxylase thermal stability. Genetic Epidemiology, 1991, 8, 237-251.	1.3	3
255	Long PCR: Selective Suppression by Restriction Endonuclease Digestion. BioTechniques, 1996, 21, 764-766.	1.8	3
256	Pharmacogenomics: Bench to Bedside. Focus (American Psychiatric Publishing), 2006, 4, 431-441.	0.8	3
257	Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 35-45.	2.4	3
258	Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics. Studies in Health Technology and Informatics, 2015, 210, 914-8.	0.3	3
259	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 3342-3355.	7.0	3
260	Studying treatment resistance in depression using patient derived neurons in vitro. Molecular Psychiatry, 2019, 24, 775-775.	7.9	2
261	Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2022, 63, 1347-1358.	5.2	2
262	Human sulfotransferase pharmacogenetics: STP2 gene, structural characterization and chromosomal localization.. Clinical Pharmacology and Therapeutics, 1996, 59, 216-216.	4.7	1
263	Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?. Pharmacogenomics, 2021, 22, 913-925.	1.3	1
264	Sulfate Conjugation. , 2005, , 61-78.		1
265	PHARMACOGENETICS AND PHARMACOGENOMICS. , 2009, , 219-224.		1
266	The Gordon Wilson Lecture. The Mayo model: one path to an academic medical center. Transactions of the American Clinical and Climatological Association, 2002, 113, 91-103; discussion 103-6.	0.5	1
267	Immune Mediator Pharmacogenomics: SNPs and Estrogen-Dependent Regulation of Inflammation. Journal of Nature and Science, 2017, 3, .	1.1	1
268	Artificial Intelligence and Pharmacogenomics. Advances in Molecular Pathology, 2019, 2, 111-118.	0.4	0
269	Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. Pharmacogenetics and Genomics, 2019, 29, 183-191.	1.5	0
270	Natriuretic Peptide Pharmacogenomics: Common Gene Sequence Variation and Functional Characterization of Membrane Metalloprotein Endopeptidase (MME). FASEB Journal, 2010, 24, 756.1.	0.5	0

#	ARTICLE	IF	CITATIONS
271	SNPs Outside Response Elements Impact Aryl Hydrocarbon Receptor (AHR) Binding and Gene Regulation: Genome-wide SNP-dependent Transcriptional Regulation. FASEB Journal, 2018, 32, 694.3.	0.5	0
272	ERICH3 Characterization: Function in Vesicular Trafficking and Antidepressant Treatment Response. FASEB Journal, 2019, 33, 680.1.	0.5	0
273	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenetics and Genomics, 2021, 31, 1-9.	1.5	0